Glenmark launches generic version of diuretic Bumetanide injection

The launch affirms commitment to Glenmark's continued focus on institutional business

Glenmark Pharmaceuticals
Press Trust of India New Delhi
1 min read Last Updated : Jan 10 2023 | 12:28 PM IST

Glenmark Pharmaceuticals Ltd on Tuesday said its US arm has launched its generic version of diuretic Bumetanide injection.

In a statement the company said Glenmark Pharmaceuticals Inc., USA (Glenmark) launched Bumetanide Injection of strengths of 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials.

These are the generic version of Bumex injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC, it added.

The launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development Portfolio, Product Launch & Strategy, Vijay Raghavan said.

The Bumex injection, 0.25 mg/mL achieved annual sales of approximately USD 16.5 million, the company said citing IQVIA sales data for the 12-month period ended November 2022.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Glenmark PharmaceuticalsPharma CompaniesUnited States

First Published: Jan 10 2023 | 12:28 PM IST

Next Story